clock menu more-arrow no yes mobile

Filed under:

23andMe and Pfizer Team Up to Study Inflammatory Bowel Disease

Personal genomics company 23andMe has partnered with pharmaceutical giant Pfizer to explore possible genetic factors associated with Inflammatory Bowel Disease, a chronic illness that affects some 1.4 million people in the United States. The companies plan to enroll and analyze the genomes of 10,000 people diagnosed with Crohn’s disease or ulcerative colitis. “We are excited to team up with Pfizer to take an innovative, consumer-centered approach to try to understand the fundamentals of inflammatory bowel disease and the variability of treatment response,” 23andMe CEO Anne Wojcicki said in a statement. Read more about the study here.

This article originally appeared on

Sign up for the newsletter Today, Explained

Understand the world with a daily explainer plus the most compelling stories of the day.